International Journal of Biological Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2024-04-18 ms8000000446605296 来自天津

3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2024-04-17 ms5000000572045221 来自安徽省

大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2024-03-04 ms6000001702952186 来自河南省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易

13 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2024-02-22 Jojo 来自北京

replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？

12 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2024-04-06 ms7000001898488025 来自北京

偏重的研究方向：分子生物学
经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀#投稿经验#

3 0

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2022-12-12 1476a8ddm35暂无昵称来自四川省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：炎症
经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01
动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。

57 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2022-11-21 503616919

偏重的研究方向：肿瘤;基因功能
经验分享：11-16 投 11-21 replace消失期待外审

53 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2023-04-14 541350208 来自重庆

今年能不能上10分

25 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2022-02-23 悬崖听风007

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫
经验分享：Received 2021-12-16 from IP
Minor revision 2022-2-8
Received 2022-2-17 from IP
Final accept 2022-2-22
Pre-publish-fee 2022-2-22
投稿到接受2个月零几天，效率杠杠的。感恩。

67 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199089, encodeId=d2772199089e6, content=3.13号投的，这都一个月多了，现在状态还是active under review,请问这是什么意思啊？多有才能有一修结果？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dc4d5547693, createdName=ms8000000446605296, createdTime=Thu Apr 18 10:48:22 CST 2024, time=2024-04-18, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2198950, encodeId=3234219895001, content=大家二审的时间是多久啊，一审给了大修more positive,修回过去20天了还是under review，好着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bc565338941, createdName=ms5000000572045221, createdTime=Wed Apr 17 13:51:38 CST 2024, time=2024-04-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2190996, encodeId=abd32190996d3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：从23年到现在，中了2篇综述。总体上，这个期刊的难度相对容易，杂志内容水平，其实差不多是6-7分的程度，但是这个杂志有9分。国人占比很高，或许也是因为分数和实际情况不太相符+国人比例过高，在一些医院被拉黑了。9分这个档次，算比较容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Mar 04 17:18:02 CST 2024, time=2024-03-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101715, encodeId=44bc2101e15f5, content=偏重的研究方向：肿瘤;基因功能 经验分享：11-16 投 11-21 replace消失期待外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77734818981, createdName=503616919, createdTime=Mon Nov 21 09:26:19 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125891, encodeId=6d6221258910f, content=今年能不能上10分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Fri Apr 14 14:11:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2159814, encodeId=fa89215981420, content=9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ed45142492, createdName=1467c29dm62(暂无昵称), createdTime=Tue Sep 26 14:54:17 CST 2023, time=2023-09-26, status=1, ipAttribution=浙江省)]

2023-09-26 1467c29dm62(暂无昵称) 来自浙江省

9.17投稿，一周后replace消失，不确定是不是送审，后续有消息再更新

39 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务